October 1, 2016
Brazil will begin to use dolutegravir in its national programme early next year. The Ministry of Health has negotiated a 70% price reduction with ViiV Healthcare.
On 28 September, the Brazilian Ministry of Health announced that it expects to be treating about 80,000 new first-line patients with dolutegravir plus 20,000 who switch from efavirenz due to side effects by the end of 2017.
Brazil has planned a phased process that will exclude pregnant women and people receiving co-treatment for TB. The agreed price is around US$ 500 per person per year for dolutegravir -- and the country has bought 40 million tablets. "We are offering this treatment without budgetary impact," said the director of the ministry Adele Benzaken. (ie at no greater cost than efavirenz). Distribution will start in January 2017.
This is very good news. At this price, the overall Brazilian HIV budget will not be affected. And this news should be a useful bargaining tool for other middle-income countries that will hopefully be able to negotiate similar price levels for dolutegravir.
Luiz G. Medicamento dolutegravir é nova opção do SUS para pacientes com HIV. 28 September 2016.
|Potential Economic Impact of Dolutegravir/3TC Dual Therapy|
|Dolutegravir: A Powerful Drug Entering Different Research Paths|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.